evogene

REAL-WORLD INNOVATION

REAL-WORLD INNOVATION

AI-first discovery platform generating multi-parameter molecules

January 7, 2026

FORWARD LOOKING STATEMENT

This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, pipeline, as well as our capabilities and technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the current war between Israel and Hamas and any further adverse impact that it may have on economic activity in Israel due to the calling up of a large number of reserve soldiers or the incurrence of debt to pay for the high cost of the war, and any accompanying future uncertainties for the security of the Company's operations in southern Israel, as well as those additional factors described in greater detailin Evogene's Annual Report on Form 20-F and in other reports Evogene files with and furnishes to the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract or commitment relating thereto or to the securities of the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

THERE IS A GAP

BETWEEN REAL-WORLD CHALLENGES
AND INNOVATIVE SOLUTIONS

UTILIZING

AI AND ADVANCED PROPRIETARY ALGORITHMS

TO DELIVER INNOVATIVE SMALL MOLECULES, TAILORED TO REAL-WORLD COMMERCIAL PRODUCT NEEDS

WE CALL IT: REAL-WORLD INNOVATION

EVOGENE PIONEERS
REAL-WORLD INNOVATION

Using a proprietary generativeAI engine, we design highly potent and novel small molecules, optimized across multiple-parameters, for the pharmaceutical and ag-chemical industries

OUR STORY IN 3 SENTENCES

GEN AI ENGINE

Design of small molecules with high probability of success

REVOLUTIONIZING AG

Proven results with strategic collaborations

PIONEERING IN PHARMA

Differentiated tech offering that fits market demand

THE DISCOVERY & OPTIMIZATION CHALLENGE

DESIGN THE RIGHT CANDIDATES TO REACH THE MARKET



LESS THAN 10% OF MOLECULES TESTED IN CLINICAL TRIALS MAKE IT TO MARKET

Discovery & optimization are the critical stages for increasing market success probability

THE MULTI-PARAMETER OPTIMIZATION **CHALLENGE**

Creating a molecule that will succeed through all development phases requires balancing in advance multiple, often competing, parameters

THE CHALLENGE FOR TRADITIONAL METHODS:

- Optimization typically limited to a small number of parameters
- Cannot address multiple-parameters simultaneously
- Requires lengthy, resource-intensive iterative cycles

INTRODUCING CHEMPASS AI:

A MULTI-PARAMETER DESIGN ENGINE FOR REAL-WORLD INNOVATION

ChemPass AI

MULTI-PARAMETER OPTIMIZATION

Optimizes multiple-parameters simultaneously, adapted to project specific chemical, biological, and physical constraints, increasing probability of success

NOVEL MOLECULAR STRUCTURES

Based on 38B molecules, the algorithm generates completely novel, synthesizable and effective compounds, extending beyond explored chemical space.

HIGHLY POTENT

AI-first designed molecules optimized through targeted experimental validation

CHEMPASS AI:
A MULTI-PARAMETER GENERATIVE DESIGN ENGINE FOR REAL-WORLD INNOVATION



CHEMPASS AI TRANSFORMS TRADITIONAL METHODS:

- Optimization of diverse product specific parameters
- Addresses multiple constraints simultaneously
- Minimizes lengthy, resource-intensive iterative cycles

CHEMPASS AI FOUNDED BY PROPRIETARY TECHNOLOGY
BOOSTING PROBABILITY OF SUCCESS

Step 1

HIT SCREENING
WITH *POINTHIT™*

Utilizing deep learning to enhance rapid screening in ultra-large databases



Step 2

HIT TO LEAD
WITH *ACTIVESEARCH™*

DMTA coupled with upgraded analog search using proprietary algorithms

UP TO 400-FOLD IMPROVEMENT

ACTIVESEARCH RESULTS	1,800
SELECTED & PURCHASED	41
ACTIVE	16
SUB MICROMOLAR POTENCY	7

Step 3

LEAD OPTIMIZATION
WITH *LEADOP GPT™*

Simultaneous optimization of multiple parameters using generative AI



REACHED MULTI-PARAMETER OPTIMIZED nMol ACTIVE NOVEL COMPOUNDS

Result

PRODUCT CANDIDATE



THE KEY FOR SUCCESS –STRATEGIC PARTNERSHIPS / INTERNAL EXPERTISE

TAILORED TO EACH CHALLENGE & OPTIMIZED FOR SUCCESS





GOOGLE CLOUD x EVOGENE

BREAKING NEW GROUND IN AI-FIRST MOLECULE DESIGN

TRANSFORMATIVE PARTNERSHIP

Combining Evogene's proprietary AI foundation model, with Google Cloud's world-class infrastructure to scale revolutionary molecular discovery

ACCELERATED INNOVATION

Google's infrastructure enabled efficient use of a massive dataset starting with millions and ultimately reaching a training set of approximately 38 billion molecular structures

3x IMPROVED ACCURACY

Optimization across multiple-parameters reached 90% precision (vs. 29% in traditional GPT AI-model)

"We're pleased to collaborate with Evogene's innovation in AI-powered molecule design. Their progress with ChemPass AI highlights the strength of pairing advanced AI infrastructure with deep scientific insight. We look forward to seeing the impact of this new model in drug discovery and agriculture."

BOAZ MAOZ, MANAGING DIRECTOR, GOOGLE CLOUD ISRAEL

OUR STORY IN 3 SENTENCES

GEN AI ENGINE

Design of small molecules with high probability of success

REVOLUTIONIZING AG

Proven results with strategic collaborations

PIONEERING IN PHARMA

Differentiated tech offering that fits market demand

agPlenus
EVOGENE'S SUBSIDIARY

A GROWING MARKET
WITH PLENTY OF ROOM FOR INNOVATION

1 Increase of pest resistance & regulatory requirements

2 Urgent need for new Modes of Action (MoAs)

3 Decreased rate in discovery of new pesticides due to lack of innovation

$43.3B
BROAD SPECTRUM HERBICIDES[1]

$22.2B
FUNGICIDES FOR MAJOR DISEASES[2]

$22.3B
BROAD SPECTRUM INSECTICIDES[3]

evogene

Company calculation based on: 1) Mordor Intelligence 2) Fortune Business Insights 3) Data Bridge

agPlenus
EVOGENE'S SUBSIDIARY

With rising pest resistance, tighter regulation, and laggard development

COMPUTATIONAL CHEMISTRY CAN CREATE REAL-WORLD IMPACT IN AGRICULTURE

STRATEGIC **COLLABORATIONS**

"Bringing together AgPlenus' expertise with Bayer's CropKey approach to crop protection innovation will help accelerate the delivery of essential, sustainable, and affordable solutions to farmers and set a new benchmark in the industry."

Rachel Rama, Head of Small Molecules, Crop Science division



Nontreated Treated

Development of new sustainable Mode-of-Action broad spectrum, herbicide

Demonstrated high weed control efficacy and good tolerance in corn

"The collaboration with AgPlenus has accelerated the identification of a class of herbicide chemistry that targets a new mode-of-action for weed control, something the industry has been lacking for decades."

Vid Hegde, Former VP of Crop Protection Discovery and Development



Treated nontreated

Development of novel herbicides

Demonstrated weed growth reduction in post emergence application

agPlenus
EVOGENE'S SUBSIDIARY

INTERNAL PIPELINE
WHEAT BLOTCH

DISRUPTING A $1.2B PROBLEM AT RECORD SPEED

- 70% of EU fungicide usage in wheat is for Wheat Blotch[1]
- EU market alone >$1.2B annually[1]
- Widespread resistance to current top products ('Strobilurins') with 2024 sales of $4.59B[2]

APTF-4 PRESENTS STRONG POTENTIAL FOR REAL-WORLD INNOVATION



- Shows clear concentration-dependent antifungal efficacy
- Ongoing optimization to enhance potency
- 18 months from target to optimized hit

evogene
1) TResearch Summer 2019 2) Global Growth Insights

OUR STORY IN 3 SENTENCES

GEN AI ENGINE

Design of small molecules with high probability of success

REVOLUTIONIZING AG

Proven results with strategic collaborations

PIONEERING IN PHARMA

Differentiated tech offering that fits market demand

GROWING OPPORTUNITY IN AI-DRUG DISCOVERY



SMALL MOLECULES

Account for
58%
Of total pharmaceutical market ($1,344B)

AI-based candidates in pipeline
>60
150% CAGR in last 3 years

Discovery market expected to reach
$190.68B
by 2034


1) DCAT Value Chain Insights 2) Science Direct 3) Precedence Research

THE DISCOVERY AND OPTIMIZATION CHALLENGE

DEVELOPING CANDIDATES THAT WILL REACH THE MARKET



evogene

https://pmc.ncbi.nlm.nih.gov/articles/PMC9293739

CHEMPASS AI: DRIVING HIGHER CUMULATIVE PROBABILITY OF SUCCESS



evogene

https://pmc.ncbi.nlm.nih.gov/articles/PMC9293739/

BUSINESS STRATEGY

CAPTURE THE VALUE OF CHEMPASS AI

through diverse collaborative partnerships to accelerate small molecule-based drug development.

PARTNERING WITH PHARMA AND BIOTECH COMPANIES

that complement our technology, enabling groundbreaking innovations that benefit both parties.



STRATEGIC **COLLABORATIONS**

UNRAVEL BIOSCIENCES

NOVEL THERAPIES FOR DEMYELINATION DISORDERS

Together, the companies will design and validate brain-penetrant inhibitors of a newly discovered demyelination target. This collaboration aims to create the first therapeutic capable of restoring myelin and improving neurological function—addressing a major unmet need in a global market exceeding $26B and growing, with strong commercial interest and clear opportunities for licensing to leading MS-focused pharmaceutical companies.

"We are thrilled to partner with Evogene to design an optimized new therapeutic candidates to promote remyelination for MS and other neurodegenerative disorders. The synergistic combination of Evogene's Chempass-AI platform and generative chemistry together with Unravel's patient RNA-derived Living Molecular Twins™ demonstrates the acceleration of drug development driven by novel data and advanced algorithms since patients cannot wait."

Dr. Richard Novak, CEO



Molecular modelling of putative modulator (green) in its target (surface in grey and interacting protein residues in colored spheres)

STRATEGIC **COLLABORATIONS**

TEL AVIV UNIVERSITY אוניברסיטת תל אביב

NEW THERAPEUTICS FOR METABOLITE DISEASE

The collaboration aims to design novel small molecules that can effectively inhibit pathological self-assembly processes, leading to transformative new therapeutics with the potential to improve the lives of millions of patients suffering from diseases including Tyrosinemia, Gout and Maple Syrup Urine Disease (MSUD).

The collaboration brings together Evogene's ChemPass AI's state-of-the-art computational capabilities for generative molecular design with **Prof. Ehud Gazit's world-renowned expertise** in the characterization and manipulation of molecular self-assembly.

Scanning electron microscopy of crystals formed by the self-assembly of a metabolite

* Costa-Bauza, A., & Grases, F. (2023). Biomolecules, 13(12), 1769.

DELIVERING REAL-WORLD INNOVATION
THROUGH TWO STRATEGIC MARKET OPERATIONS

ChemPass AI

PHARMA DIVISION

EXTERNAL COLLABORATIONS

Tel Aviv University — Metabolic Disease

UNRAVEL BIOSCIENCES — Demyelination Disorders

INTERNAL PIPELINE

Undisclosed

agPlenus
EVOGENE'S SUBSIDIARY

STRATEGIC COLLABORATION

BAYER — Herbicides

CORTEVA agriscience — Herbicides

INTERNAL PIPELINE

Wheat Blotch

evOgene

Creating

REAL-WORLD INNOVATION

for a better future